Brain lithium play defying the dip 🧠

And it just announced a milestone achievement this morning

November 19, 2025

Markets are getting smoked but this little pharma stock just dropped news that they finished the clinical part of a big trial with Mass General/Harvard and the pre-market is liking it. I've been nailing tactical trades all week in this mess, and ALZN is my top watch today for a potential bounce.

TODAY’S TOP ALERT! 

Alzamend Neuro (Nasdaq: ALZN)

👉  ALZN is TODAY’S #1 ALERT 👈

Hey Folks, happy Hump Day,

It has been a banner week so far for my “tactical trade” ideas…

Markets have been tanking the last four trading sessions, with the S&P 500 now down 3.4% and the Nasdaq down 4.2%.

Investors are pulling out of the AI trade ahead of NVDA earnings later today, and that has really taken its toll…

Still, I’ve managed to identify three killer trade ideas this week. On Monday, I alerted a biotech that surged as high as 26% that day.

And yesterday, I alerted these double-digit winners:

Stock futures are pointing to a potential rebound today, and I’m excited for what could be in store.

The stock I’m focused on today is Alzamend Neuro, Inc. (ALZN).

The stock has been defying the markets over the past four trading days (it’s up 4.3%), and this morning, the company announced news of the completion of the clinical portion of a critical Phase II clinical trial.

As detailed below, the company is partnering with Massachusetts General Hospital to conduct five Phase II trials. This first one was in healthy patients to establish a foundational reference for the other trials.

We learned that topline data from this first trial will come out in Q1 2026, and the rest of the trials are all expected to be initiated next year.

The pre-market is responding well to the news, and I think this could end up being a big day for ALZN. Stay locked in to see how it plays out!

👉  ALZN is TODAY’S #1 ALERT 👈

ALZN is a clinical-stage biopharmaceutical company developing novel treatments for Alzheimer’s, bipolar disorder (BD), Major depressive disorder (MDD), and PTSD.

As I’m sure you know, these diseases are huge problems. More than 43 million Americans suffer from them.

The Atlanta-based company has two main candidates, AL001 and ALZN002.

Its lead candidate, AL001, is a patented ionic cocrystal technology that delivers a therapeutic combination of lithium, proline, and salicylate. 

The company believes it is a potential replacement to current lithium treatments (lithium carbonate and lithium citrate) and could provide significant benefit to patients suffering with Alzheimer’s disease, BD, MDD and PTSD.

You’ve probably heard about lithium as a treatment for various psychiatric disorders, especially bipolar disorder, for which it is considered the gold standard treatment…

AL001 is designed to provide the benefits of traditional lithium while reducing its harmful side effects. It’s intended to distribute lithium more safely in the brain, avoiding high levels in other organs and making it safer and more convenient for patients.

ALZN is hopeful that its formulation could supplant marketed lithium therapies, and — critically — not require Therapeutic Drug Monitoring (TDM) the way those therapies do.

Preclinical data “showed prevention of cognitive deficits, depression and irritability in . . . mice,” and AL001 was found to be superior at “improving associative learning, memory, and irritability, compared with lithium carbonate treatments.”

And Phase I and Phase IIa trials confirmed that AL001, at a lithium content equivalent to 150 mg lithium carbonate, is bioequivalent to 300 mg of the currently marketed lithium carbonate capsule. 

In August 2024, ALZN announced a partnership with Massachusetts General Hospital and Harvard Medical School for five Phase II clinical trials of AL001, involving healthy human subjects and patients with Alzheimer’s Disease, Bipolar Disorder, Major Depressive Disorder, PTSD, and healthy human subjects. 

The first of the five clinical trials, which began in May 2025 in healthy human subjects, is using advanced imaging to validate AL001’s brain biodistribution, potentially accelerating approval for Bipolar Disorder, Depression, and PTSD via the 505(b)(2) regulatory pathway. 

AL001 could also complement SSRI antidepressants — which carry a black box warning for suicidal risks in younger populations — by enhancing safety and efficacy for a broader patient base. 

As mentioned, the clinical portion of that first Phase II trial is now complete, and topline data is expected in Q1 2026.

ALZN notes that “Mass General is the original and largest clinical education and research facility of Harvard Medical School/Harvard University and houses the world's largest hospital-based research program.”

Interestingly, in February 2025 the company announced the creation of a special head coil by Tesla Dynamic Coils for the purpose of precisely mapping lithium within the brain. It said the new coil would be a key component of the clinical trials at Mass General.

Tesla Head Coil

An unrelated Harvard Medical School study highlighted in major media this past August, researchers discovered that restoring the brain’s endogenous lithium levels can help prevent and even reverse Alzheimer’s disease.

ALZN’s other key candidate is ALZN002 — a patented “active” immunotherapy product that uses “a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s.”

The idea is to take white blood cells from a patient’s body and engineer them to attack Alzheimer’s-related amyloid-beta proteins. 

The company hopes this will provide a safe and effective treatment for Alzheimer’s sufferers that requires considerably less frequent treatment visits compared to passive immunity approaches of the currently marketed immunotherapies.

ALZN began a Phase I/IIA clinical trial for ALZN002 in 2023 but the contract research organization (CRO) terminated its agreement the next year.

In July 2025, ALZN said it was hunting for a new CRO, but “the process has been slower than expected due to the trial’s scientific and operational complexities, a limited pool of CROs with the necessary expertise and capacity, and industry-wide challenges, including a shortage of experienced providers and high demand for specialized trial management.”

Over at TipRanks, two analysts reiterated their price targets on ALZN in September. Maxim Group has a $6.90 target and Ascendiant has a $42 price target.

Folks, those are 182% and 1,620% higher than yesterday’s closing price.

As you do your own research, be sure to review this October 2025 investor presentation as well as the company website.

And of course, always approach your trading in a responsible manner, remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom Line: Just this morning, ALZN announced the completion of the clinical portion of its first Phase II trial of AL001. 

The stock has already been bucking the markets over the last few days, and the pre-market is responding well, so I’m keeping ALZN at the top of my watchlist today to follow all the action!

To Your Success,

Jeff Bishop

P.S. Join us all morning in the Market Master’s Trading Room for live action! Special event with Jeff Williams happening at 12pm EST —> traders click here.

*DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you're r to own any shares in Alzamend Neuro, Inc, whoever ultimately paid them most likely ownseading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty five thousand dollars (cash) from Sica Media for advertising Alzamend Neuro, Inc for a one day marketing program on November 19, 2025. Previously, we received fifteen thousand dollars (cash) from Sica Media for advertising Alzamend Neuro, Inc for a one day marketing program starting on August 18, 2025. To date, we have received forty thousand dollars for advertising Alzamend Neuro, Inc.

It might seem obvious, but while our client claims not to own any shares in Alzamend Neuro, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into Alzamend Neuro, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.